Jamie Cesanek

Data from the FORTE trial were presented at the 18th International Myeloma Workshop.

Overall response rate was 95%, including 75% of patients who achieved a complete response (CR) or better, with a median follow-up of 5.8 months at data cutoff.

The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.